/TIGERMED - [Overseas Regulatory Announcement - Corporate Governance Related Matters] — 2026033002317
NEWS

TIGERMED - [Overseas Regulatory Announcement - Corporate Governance Related Matters] — 2026033002317

HKEXnews
2026/03/30[Overseas Regulatory Announcement - Corporate Governance Related Matters]

TIGERMED - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

HANGZHOU TIGERMED CONSULTING CO., LTD.

Hangzhou Tiger Pharmaceutical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 3347)

Overseas regulatory announcement

This announcement is made by Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (the "Company") pursuant to a Hong Kong joint transaction made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Chairman Ye Xiaoping

Hong Kong, March 30, 2026

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Wen Zengyu Mr.; the independent non-executive directors are Mr. Liao Qiyu, Mr. Yuan Huagang and Ms. Liu Yuwen.

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Report on the performance of supervisory responsibilities by the audit committee of the board of directors on the accounting firm

According to the "Company Law of the People's Republic of China", "Code of Governance of Listed Companies" and "Shenzhen Stock Exchange Listing

Corporate Self-Regulation Guidelines No. 2 - Standardized Operations of GEM Listed Companies and other relevant regulations, Hangzhou Tiger The Audit Committee of the Board of Directors of Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") will now

The report on the performance of supervision responsibilities by the Firm (Special General Partnership) (hereinafter referred to as "Longxin") is as follows:

  1. Basic situation of accounting firms in 2025 annual audit

  2. Basic information of accounting firms

Lixin Accounting Firm (Special General Partnership) was founded in 1927 by Dr. Pan Xulun, a leading accounting expert in China.

Haichuang was reestablished in 1986 and became the first special general partnership accounting firm in the country to complete restructuring in 2010.

The registered address is 4th Floor, No. 61, Nanjing East Road, Huangpu District, Shanghai. Lixin is a member of the international accounting network BDO

The firm has been engaged in the securities service business for a long time. It had securities and futures business licenses before the implementation of the new securities law, and had H

It is qualified to audit stocks and has registered with the U.S. Public Company Accounting Oversight Board (PCAOB).

  1. Accounting firm personnel As of the end of 2025, Lixin has 300 partners, 2,523 certified public accountants, and a total of 9,933 employees.

There are 802 certified public accountants who have signed audit reports on securities services business.

  1. Business scale of accounting firm

Lixin’s business income (unaudited) in 2025 is 5.00 billion yuan, of which audit business income is 3.672 billion yuan, certified

Securities business income was 1.505 billion yuan. In 2025, Lixin provided annual report audit services for 770 listed companies.

The cost is 916 million yuan.

  1. Procedures for hiring an accounting firm

The first meeting of the Audit Committee of the fifth session of the Board of Directors in 2025 and the fourteenth meeting of the fifth session of the Board of Directors

and the 2024 shareholders’ meeting reviewed and approved the “Proposal on Engaging the Company’s Audit Institution for 2025” and agreed to continue Appoint Lixin as the company's 2025 auditor.

  1. Supervision of accounting firms by the audit committee

According to the company's "Working Rules of the Audit Committee of the Board of Directors" and other relevant regulations, the audit committee

The conditions for performing supervisory responsibilities are as follows:

  1. The company held the first meeting of 2025 of the fifth session of the Board of Directors’ Audit Committee on March 25, 2025 to review

The "Proposal on Hiring the Company's Audit Institution for 2025" was passed at the meeting. After reviewing the basic information of Lixin, Director

The Audit Committee of the Board of Directors believes that it has the qualifications and professional ability to provide audit work for the company and agrees to submit the proposal Submitted to the sixth meeting of the company's fifth board of directors for review.

  1. On December 29, 2025, the fourth meeting of the 2025 Audit Committee of the fifth session of the Board of Directors of the company reviewed and approved

We passed the "Preliminary Communication Letter with Governance" and other proposals, and listened to the signing accountant of Lixin Firm on the relationship between certified public accountants and those with governance.

Responsibilities related to the audit of financial statements, planned audit scope and time and personnel arrangements, independence statement, closed

Report on major matters of note.

  1. On March 27, 2026, the first meeting of the Audit Committee of the fifth session of the Board of Directors of the company in 2026 was reviewed and approved.

The "2025 Management Proposal", "2025 Annual Report" and other proposals were passed, and the audit of the financial statements was completed.

We fully communicated on matters such as the situation and the company’s cooperation with the audit. The Audit Committee of the Board of Directors considers that relevant reports truly and objectively reflect the actual situation of the company in terms of operation, management and finance, and agree to submit relevant proposals

Reviewed at the 23rd meeting of the company's fifth session of the Board of Directors.

  1. Overall evaluation

The Company’s Audit Committee strictly abides by the China Securities Regulatory Commission, Shenzhen Stock Exchange, and the “Directors

"Working Rules of the Audit Committee of the Audit Committee" and other relevant regulations, give full play to the role of professional committees, and regulate accounting affairs

The relevant qualifications and professional abilities of the accounting firm were reviewed, and full consultation was conducted with the accounting firm during the audit of the annual report.

discussion and communication, and urge accounting firms to issue audit reports in a timely, accurate, objective and fair manner, and effectively

The audit committee has fulfilled its supervisory responsibilities over the accounting firm.

Board of Directors of Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

March 31, 2026